{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-116795","form_type":"8-K","ticker":"SGMT","cik":"0001400118","company_name":"Sagimet Biosciences Inc.","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.902452+00:00","generated_at":"2026-06-08T04:46:32.421530+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Sagimet reports Q3 net loss of $6.4M; cash $101.8M; NASH data due Q1 2024","bullets":["Net loss $6.4M vs $7.5M in Q3 2022; revenue $2.0M from milestone vs zero year-ago.","Cash $101.8M, expected to fund operations at least 12 months.","Phase 2b FASCINATE-2 (denifanstat) week 52 liver biopsy results expected Q1 2024.","Two AASLD abstracts accepted; preclinical FASN inhibitor + semaglutide combo data shown.","Ascletis enrolled 120 patients in Phase 3 denifanstat + bevacizumab for recurrent GBM."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-116795","json":"https://secwatch.observer/filing/0001104659-23-116795.json","markdown":"https://secwatch.observer/filing/0001104659-23-116795.md","text":"https://secwatch.observer/filing/0001104659-23-116795.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1400118/000110465923116795/0001104659-23-116795-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1400118/000110465923116795/tm2330502d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T04:46:32.421530+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"47b42994e4132de3ac1e721615351a79920a191a","claim":"Sagimet Biosciences Inc. reported the third quarter ended September 30, 2023 results: revenue Revenues for the third quarter ended September 30, 2023 were $2.0 million, net income Net loss for the third quarter ended September 30, 2023 was $6.4 million.","evidence_excerpt":"On November 13, 2023, Sagimet Biosciences Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1400118/000110465923116795/0001104659-23-116795-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Revenue","value":"Revenues for the third quarter ended September 30, 2023 were $2.0 million"},{"label":"Net income","value":"Net loss for the third quarter ended September 30, 2023 was $6.4 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}